We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
Read MoreHide Full Article
Key Takeaways
Thermo Fisher launched Orbitrap Astral Zoom and Orbitrap Excedion Pro to advance research in complex diseases.
TMO's Orbitrap Astral Zoom offers 35% faster scans, 40% more throughput and 50% better multiplexing.
TMO's Orbitrap Excedion Pro combines hybrid MS with new tech for faster, higher-quality biomolecule analysis.
Thermo Fisher Scientific Inc. (TMO - Free Report) recently launched the Thermo Scientific Orbitrap Astral Zoom mass spectrometer (MS) and the Thermo Scientific Orbitrap Excedion Pro MS at the American Society for Mass Spectrometry’s annual conference in Baltimore, MD. The instruments are built to reveal intricate biological mechanisms that may drive progress in precision medicine and offer valuable insights into complex diseases, such as Alzheimer’s and cancer.
The latest launch enhances Thermo Fisher’s industry-leading Life Sciences Solutions portfolio.
Likely Trend of TMO Stock Following the News
After the announcement yesterday, TMO shares lost 1.6%, closing at $396.47.
On a positive note, in recent years, Thermo Fisher has gradually ramped up investment in R&D. The company is launching a slew of products, enhancing its portfolio. Henceforth, we expect that the latest launch will positively boost the market sentiment toward TMO stock in the upcoming days.
Presently, Thermo Fisher boasts a market capitalization of $149.67 billion. The Zacks Consensus Estimate forecasts a 2.1% increase in the company’s earnings and 1.9% growth in revenues, both on a year-over-year basis. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.3%.
About TMO’s Orbitrap Astral Zoom MS
Expanding on the success of the Thermo Scientific Orbitrap Astral mass spectrometer, the Orbitrap Astral Zoom MS delivers unparalleled performance and is engineered to drive the next wave of breakthroughs in scientific research. The instrument enables 35% faster scan speeds, 40% higher throughput and 50% expanded multiplexing capabilities, delivering higher sensitivity and increased experimental flexibility.
About TMO’s Orbitrap Excedion Pro MS
The Thermo Scientific Orbitrap Excedion Pro MS offers enhanced performance to accelerate biological drug development. The Orbitrap Excedion Pro is the first platform to combine next-generation Orbitrap hybrid mass spectrometry with alternative fragmentation technologies, a technique for efficiently analyzing complex biomolecules. With enhanced sensitivity, dynamic range and reliability, the Orbitrap Excedion Pro MS delivers faster, higher-quality protein and post-translational modification data along with small molecule insights to drive robust biological understandings.
Image Source: Zacks Investment Research
Industry Prospects Favor TMO Stock
Per a report by Grand View Research, the global mass spectrometry market size is projected to witness a compound annual growth rate of 8% from 2025 to 2030. Increasing R&D in the pharmaceutical and biotechnology industries is expected to drive the adoption of mass spectrometers. Moreover, advancements in proteomics research and the rapid growth of biomedical research are other factors contributing to market growth.
Another Recent Launch by TMO
Thermo Fisher recently unveiled its latest innovation, the spectral-enabled Invitrogen Attune Xenith Flow Cytometer. The solution allows immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples.
TMO Stock Price Performance
In the past year, TMO shares have plunged 30.4% compared with the industry’s 12.2% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Hims & Hers Health (HIMS - Free Report) and Prestige Consumer Healthcare (PBH - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry’s 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry’s 0.5% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company’s 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
Estimates for Prestige Consumer Healthcare’s fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry’s 10.1% growth. PBH’s earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TMO Launches Next-Generation Mass Spectrometers: Stock to Gain?
Key Takeaways
Thermo Fisher Scientific Inc. (TMO - Free Report) recently launched the Thermo Scientific Orbitrap Astral Zoom mass spectrometer (MS) and the Thermo Scientific Orbitrap Excedion Pro MS at the American Society for Mass Spectrometry’s annual conference in Baltimore, MD. The instruments are built to reveal intricate biological mechanisms that may drive progress in precision medicine and offer valuable insights into complex diseases, such as Alzheimer’s and cancer.
The latest launch enhances Thermo Fisher’s industry-leading Life Sciences Solutions portfolio.
Likely Trend of TMO Stock Following the News
After the announcement yesterday, TMO shares lost 1.6%, closing at $396.47.
On a positive note, in recent years, Thermo Fisher has gradually ramped up investment in R&D. The company is launching a slew of products, enhancing its portfolio. Henceforth, we expect that the latest launch will positively boost the market sentiment toward TMO stock in the upcoming days.
Presently, Thermo Fisher boasts a market capitalization of $149.67 billion. The Zacks Consensus Estimate forecasts a 2.1% increase in the company’s earnings and 1.9% growth in revenues, both on a year-over-year basis. It surpassed earnings estimates in each of the trailing four quarters, delivering an earnings surprise of 2.3%.
About TMO’s Orbitrap Astral Zoom MS
Expanding on the success of the Thermo Scientific Orbitrap Astral mass spectrometer, the Orbitrap Astral Zoom MS delivers unparalleled performance and is engineered to drive the next wave of breakthroughs in scientific research. The instrument enables 35% faster scan speeds, 40% higher throughput and 50% expanded multiplexing capabilities, delivering higher sensitivity and increased experimental flexibility.
About TMO’s Orbitrap Excedion Pro MS
The Thermo Scientific Orbitrap Excedion Pro MS offers enhanced performance to accelerate biological drug development. The Orbitrap Excedion Pro is the first platform to combine next-generation Orbitrap hybrid mass spectrometry with alternative fragmentation technologies, a technique for efficiently analyzing complex biomolecules. With enhanced sensitivity, dynamic range and reliability, the Orbitrap Excedion Pro MS delivers faster, higher-quality protein and post-translational modification data along with small molecule insights to drive robust biological understandings.
Image Source: Zacks Investment Research
Industry Prospects Favor TMO Stock
Per a report by Grand View Research, the global mass spectrometry market size is projected to witness a compound annual growth rate of 8% from 2025 to 2030. Increasing R&D in the pharmaceutical and biotechnology industries is expected to drive the adoption of mass spectrometers. Moreover, advancements in proteomics research and the rapid growth of biomedical research are other factors contributing to market growth.
Another Recent Launch by TMO
Thermo Fisher recently unveiled its latest innovation, the spectral-enabled Invitrogen Attune Xenith Flow Cytometer. The solution allows immunology and immuno-oncology researchers to automate and streamline workflows to obtain more detailed and accurate insights from critical cellular samples.
TMO Stock Price Performance
In the past year, TMO shares have plunged 30.4% compared with the industry’s 12.2% decline.
TMO’s Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Hims & Hers Health (HIMS - Free Report) and Prestige Consumer Healthcare (PBH - Free Report) . While Phibro Animal Health sports a Zacks Rank #1 (Strong Buy) at present, Hims & Hers Health and Prestige Consumer Health each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Phibro Animal Health’s fiscal 2025 earnings per share have jumped 3.6% to $2.01 in the past 30 days. Shares of the company have rallied 37.9% in the past year compared with the industry’s 10.1% growth. Its earnings yield of 8.7% compares comfortably with the industry’s 0.5% yield. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 30.6%.
Hims & Hers Health shares have surged 172.5% in the past year. Estimates for the company’s 2025 earnings per share have jumped 12.5% to 72 cents in the past 30 days. HIMS’ earnings beat estimates twice in the trailing four quarters, matched in one and missed on another occasion, the average surprise being 19.6%. In the last reported quarter, it posted an earnings surprise of 66.7%.
Estimates for Prestige Consumer Healthcare’s fiscal 2026 earnings per share have increased 1 cent to $4.77 in the past 30 days. Shares of the company have jumped 37.2% in the past year compared with the industry’s 10.1% growth. PBH’s earnings surpassed estimates in three of the trailing four quarters and matched on one occasion, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 1.5%.